US Food and Drug Administration (USFDA) has concluded an inspection at Alkem Laboratories’ Bioequivalence facility located at Taloja in the state of Maharashtra from November 08 to 14, 2018. At the end of the inspection, no Form 483 was issued.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.